Overcoming Endocrine Resistance in Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Based on these results it can be envisioned that the majority of endocrine-responsive
post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy
(front-line, switching or extending) and/or as first-line management of metastatic breast
cancer.